Kay NE - Search Results

1

Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.

Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. Fonseca R, et al. Among authors: kay ne. Cancer Res. 2002 Feb 1;62(3):715-20. Cancer Res. 2002. PMID: 11830525

2

Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.

Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B. Billadeau D, et al. Blood. 1992 Oct 1;80(7):1818-24. Blood. 1992. PMID: 1391945 Free article.

3

B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors.

Zaknoen SL, Christian SL, Suen R, Van Ness B, Kay NE. Zaknoen SL, et al. Among authors: kay ne. Leukemia. 1992 Jul;6(7):675-9. Leukemia. 1992. PMID: 1625486

4

Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease.

Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Billadeau D, et al. Blood. 1991 Dec 1;78(11):3021-9. Blood. 1991. PMID: 1954387 Free article.

5

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study.

O'Connell MJ, Colgan JP, Oken MM, Ritts RE Jr, Kay NE, Itri LM. O'Connell MJ, et al. Among authors: kay ne. J Clin Oncol. 1986 Feb;4(2):128-36. doi: 10.1200/JCO.1986.4.2.128. J Clin Oncol. 1986. PMID: 3511183 Clinical Trial.

6

Lymphocytotoxic T lymphocytes in a patient with B-chronic lymphocytic leukemia and pure red cell aplasia.

Kay NE, Oken MM, Ascensao J, Kaplan ME. Kay NE, et al. Leuk Res. 1985;9(9):1189-94. doi: 10.1016/0145-2126(85)90110-9. Leuk Res. 1985. PMID: 3877853

7

The influential T cell in B-cell neoplasms.

Kay NE, Oken MM, Perri RT. Kay NE, et al. J Clin Oncol. 1983 Dec;1(12):810-6. doi: 10.1200/JCO.1983.1.12.810. J Clin Oncol. 1983. PMID: 6230420 Review.

8

Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma.

Perri RT, Oken MM, Kay NE. Perri RT, et al. Among authors: kay ne. J Lab Clin Med. 1982 Apr;99(4):512-9. J Lab Clin Med. 1982. PMID: 6460827

9

T-cell subpopulations in multiple myeloma: correlation with clinical disease status.

Oken MM, Kay NE. Oken MM, et al. Among authors: kay ne. Br J Haematol. 1981 Dec;49(4):629-34. doi: 10.1111/j.1365-2141.1981.tb07273.x. Br J Haematol. 1981. PMID: 6976183

10

Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group.

Kay NE, Oken MM, Bone N, Kyle RA, Greipp P, Van Ness B, Leong T. Kay NE, et al. Blood. 1995 Nov 15;86(10):4000-1. Blood. 1995. PMID: 7579374 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

473 results

Search Page

Filters